GW Pharmaceuticals
GW Pharmaceuticals is a British pharmaceutical company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[4] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018.[5]
Public Limited Company | |
Traded as | NASDAQ: GWPH |
Industry | Pharmaceutical |
Founded | 1998 |
Founder | Geoffrey Guy and Brian Whittle |
Headquarters | Cambridge, United Kingdom[1] |
Key people | Justin Gover (CEO)[2] |
Products | Epidiolex (Epidyolex in Europe), Sativex |
Revenue | $311 million (2019)[3] |
Divisions | Biotechnology |
Website | www |
History
GW Pharmaceuticals was founded in 1998 by Doctors Geoffrey Guy and Brian Whittle. That year, they obtained a cultivation license from the United Kingdom Home Office and the MHRA, allowing the company to cultivate, possess and supply cannabis to conduct scientific research concerning medicinal uses of the plant.[6][7]
Later that year, GW Pharmaceuticals entered into a contract with HortaPharm B.V., a cannabis research and development corporation based in Amsterdam.[8] The company was founded by two expert horticulturists from California,[9] Robert Connell Clarke[10] and David Paul Watson, and grew and developed specialized strains of cannabis with permission from the Dutch government.[11][12][13][14]
In 2001, GW Pharmaceuticals listed on AIM, the junior market of the London Stock Exchange.[15] In May 2013, the company became dual-listed on the NASDAQ and AIM.[16]
Marketed products
Sativex
Nabiximols (trade name Sativex) is a botanical drug that is a cannabis extract, administered as a mouth spray; it was approved in the UK in 2010 as a treatment for multiple sclerosis (MS) patients to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms.[17]
Nabiximols is made with two unknown Cannabis strains, and is extracted with ethanol and carbon dioxide.[18][19]
In 2011, GW Pharmaceuticals concluded a partnership with Bayer for the distribution of Sativex in the UK,[20] and have an estimated annual production of 100 tons of medicinal cannabis since 2012.[21]
Epidiolex
In 2015 GW Pharmaceutical initiated Phase 3 clinical trials of cannabidiol oral solution for treatment of two orphan conditions in children – Dravet and Lennox-Gastaut syndromes.[22][23] GW also received fast track designation from the US FDA for use of the drug candidate to treat newborns with epilepsy.[24]
The drug, under the brand name Epidiolex, was given US FDA approval in June 2018.[25][26]. It was subsequently given European EMA approval in September 2019 under the brand name Epidyolex.[27][28]
See also
- Dronabinol
- Marinol
- Nabilone
- Medical use of cannabis
References
- "GW Pharmaceuticals Ltd". 17 August 2017.
- https://www.theguardian.com/business/2011/apr/17/gw-pharmaceuticals-justin-gover-cannabis-sativex-multiple-sclerosis?INTCMP=SRCH The Observer, Sunday 17 April 2011)
- https://www.globenewswire.com/news-release/2020/02/25/1990437/0/en/GW-Pharmaceuticals-plc-Reports-Fourth-Quarter-and-Year-End-2019-Financial-Results-and-Operational-Progress.html. Missing or empty
|title=
(help) - Elizabeth Landau (21 June 2010). "World's first fully approved cannabis drug on sale in UK". Thechart.blogs.cnn.com.
- Debra Goldschmidt and Susan Scutti. "FDA approves first cannabis-based drug". CNN. Retrieved 7 August 2019.
- Pete Brady (25 April 2003). "GW Pharm responds to CC". Cannabisculture.com. Archived from the original on 12 November 2013.
- Mary Lynn Mathre, R. N. (July 1997). Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (Google eBook). ISBN 9780786403615 – via Google Books.
- "The Inheritance of Chemical Phenotype in Cannabis sativa L.(HortaPharm B.V., 1075 VS, Amsterdam, The Netherlands and Instituto Sperimentale per le Colture Industriali, 40128 Bologna, Italy)". Genetics.org. 1 January 2003.
- "sam-the-skunkman [Four Twenty Wiki]". Fourtwentywiki.com. 16 August 2011.
- "inauthor:"Robert Connell Clarke" – Google Search".
- Marks, MD; Tian, L; Wenger, JP; et al. (2009). "Seeds from the marijuana cultivar Skunk no. 1 were provided by HortaPharm BV (Amsterdam, The Netherlands) and imported under a US Drug Enforcement Administration (DEA) permit to a registered controlled substance research facility". J. Exp. Bot. 60 (13): 3715–26. doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
- "Details released of collaboration between GW Pharmaceuticals and HortaPharm medicinal cannabis". Gwpharm.com.
- Breen, Bill (1 February 2004). "The Cannabis Conundrum". Fastcompany.com.
- Breen, Bill (1 February 2004). "Dr. Dope's Connection". Fastcompany.com.
- "GW Pharma aims for $150m in Nasdaq offering". Financial Times. Retrieved 6 July 2018.
- "UK Cannabis Grower on a High With Wall Street Funding Bid". International Business Times UK. 21 December 2013. Retrieved 23 August 2019.
- UK Medicines Online Nabiximols Page accessed 3 February 2016
- "Extraction of pharmaceutically active components from plant materials". Patentstorm.us. Archived from the original on 6 October 2012. Retrieved 18 July 2012.
- "Is Big Pharma set to corner the American market on medical marijuana?". Americanindependent.com. 25 April 2011. Archived from the original on 22 July 2012.
- "GWPharma – GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment". Gwpharm.com. 30 September 2004. Archived from the original on 21 October 2016. Retrieved 18 July 2012.
- "Medical Cannabis Strains – Geoffrey Guy, MD (GW Pharmaceuticals, UK (Conference)". Youtube.com. 23 February 2010.
- Ward, Andrew (9 January 2014). "GW raises nearly $90m to develop childhood epilepsy treatment". Financial Times. Retrieved 20 January 2014.
- Butticè, Claudio (9 December 2015). "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News. Retrieved 3 February 2016.
- Tony Quested for Business Weekly. 6 August 2015 FDA backs cannabis-based medicine for in-danger newborns
- "FDA approves country's first medicine made from marijuana - STAT". STAT. 25 June 2018. Retrieved 25 June 2018.
- Julia Kollewe (25 June 2018), "UK epilepsy drug to become first cannabis-based medicine in US", The Guardian
- [ema.europa.eu/en/medicines/human/EPAR/epidyolex#authorisation-details-section ema.europa.eu/en/medicines/human/EPAR/epidyolex#authorisation-details-section] Check
|url=
value (help). Missing or empty|title=
(help) - https://www.bbc.co.uk/news/health-49795260. Missing or empty
|title=
(help)